ClinicalTrials.gg

Program

HPB-092

A development code. Also written as “HPB-092 tablet”.

Its studies are mostly in Leukemia, Myeloid, Acute, led by Hangzhou Polymed Biopharmaceuticals.

Furthest: phase 1, since Jul 31, 20251 company-led study, 1 open or runningNext primary completion: Jun 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hangzhou Polymed Biopharmaceuticals11 open or runningphase 1since Jul 31, 2025Jul 31, 2025Jun 2027phase 1 · NCT07137637

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 31, 2025First study: phase 1 study in RecurrenceFirst studyNCT07137637 · 60 planned · China

Ahead

  1. Jun 2027Primary completion: phase 1 study in RecurrenceNCT07137637

TargetBeta

FLT3 →IRAK4 →read by rule
“HPB-092 is an effective dual inhibitor of FLT3 and IRAK4, exhibiting high selectivity, favorable absorption, distribution, metabolism, and excretion (ADME) properties, as well as strong anti-leukemic efficacy.”study text, by rule · the study

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07137637Recurrence · China1RecruitingJun 202760

How it is read

Names in the registry

  • “HPB-092 tablet”, 1 entry

Codes read as this program: HPB092.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.